MCID: BLD051
MIFTS: 48

Blood Coagulation Disease

Categories: Blood diseases, Genetic diseases

Aliases & Classifications for Blood Coagulation Disease

MalaCards integrated aliases for Blood Coagulation Disease:

Name: Blood Coagulation Disease 12 15 17
Blood Coagulation Disorders 75 44 72
Postpartum Coagulation Defect with Delivery 12
Postpartum Coagulation Defect 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1247
ICD9CM 35 286
MeSH 44 D001778
NCIt 50 C2902
SNOMED-CT 68 64779008
ICD10 33 D68.9 O72.3
UMLS 72 C0005779

Summaries for Blood Coagulation Disease

MalaCards based summary : Blood Coagulation Disease, also known as blood coagulation disorders, is related to inherited blood coagulation disease and antithrombin iii deficiency. An important gene associated with Blood Coagulation Disease is VWF (Von Willebrand Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Phylloquinone and Anti-inhibitor coagulant complex have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and brain, and related phenotypes are no effect and hematopoietic system

Wikipedia : 75 Coagulopathy (also called a bleeding disorder) is a condition in which the blood's ability to coagulate... more...

Related Diseases for Blood Coagulation Disease

Diseases in the Blood Coagulation Disease family:

Inherited Blood Coagulation Disease

Diseases related to Blood Coagulation Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 inherited blood coagulation disease 32.8 VWF SERPINC1 ITGB3 ITGA2B GP9 GP1BA
2 antithrombin iii deficiency 32.6 SERPINC1 MTHFR F2
3 bleeding disorder, platelet-type, 16 32.5 ITGB3 ITGA2B
4 pseudo-von willebrand disease 32.5 VWF GP9 GP1BA
5 acquired von willebrand syndrome 32.5 VWF GP1BA F9 F8
6 prothrombin deficiency, congenital 32.5 SERPINC1 F2
7 gray platelet syndrome 32.4 VWF GP9 CD40LG
8 factor vii deficiency 32.3 F9 F8 F7 F3 F2
9 hemophilia b 32.1 SERPINC1 F9 F8 F7 F3 F2
10 factor v deficiency 32.1 VWF F9 F8 F7 F3 F2
11 bernard-soulier syndrome 31.4 VWF THPO ITGB3 ITGA2B GP9 GP1BA
12 glanzmann thrombasthenia 31.2 VWF ITGB3 ITGA2B GP9 GP1BA F9
13 factor viii deficiency 31.2 VWF F8 F2
14 heparin-induced thrombocytopenia 30.9 SERPINC1 F3 CD40LG
15 liver cirrhosis 30.8 THPO SERPINC1 F3 F2
16 dysfibrinogenemia 30.8 THBD SERPINC1 F2
17 hemophilia a 30.7 VWF F9 F8 F7 F3
18 hemophilia 30.7 VWF F9 F8 F7 F3 F2
19 vasculitis 30.6 VWF THBD CD40LG
20 portal hypertension 30.6 VWF THPO F2
21 placental abruption 30.6 THBD SERPINC1 MTHFR F2
22 thrombotic thrombocytopenic purpura 30.5 VWF THBD F3 ADAMTS13
23 varicose veins 30.4 VWF SERPINC1 MTHFR F2
24 thrombophlebitis 30.4 SERPINC1 MTHFR F8 F2
25 disseminated intravascular coagulation 30.4 THBD SERPINC1 F9 F7 F3 F2
26 von willebrand's disease 30.4 VWF GP1BA F9 F8 F3 F2
27 factor x deficiency 30.1 VWF SERPINC1 F9 F7 F3 F2
28 polycythemia vera 29.9 THPO THBD PF4 MPL ITGB3
29 hellp syndrome 29.7 VWF THBD SERPINC1 MTHFR F3 F2
30 thrombophilia 29.7 VWF THBD SERPINC1 MTHFR F9 F8
31 thrombophilia due to thrombin defect 29.7 VWF THBD SERPINC1 MTHFR F8 F3
32 thrombocytopenia 29.4 THPO PF4 MPL ITGB3 ITGA2B GP9
33 vascular disease 29.3 VWF THBD SERPINC1 MTHFR ITGB3 GP1BA
34 thrombophilia due to activated protein c resistance 29.1 VWF THBD SERPINC1 PF4 MTHFR F9
35 purpura 29.1 VWF THPO THBD SERPINC1 MPL ITGB3
36 thrombosis 28.7 VWF THBD SERPINC1 PF4 MTHFR GP1BA
37 bleeding disorder, platelet-type, 17 11.1
38 scott syndrome 11.1
39 quebec platelet disorder 11.1
40 bleeding disorder, platelet-type, 12 11.1
41 platelet glycoprotein iv deficiency 11.1
42 bleeding disorder, platelet-type, 8 11.1
43 bleeding disorder, platelet-type, 14 11.1
44 bleeding disorder, platelet-type, 9 11.1
45 bleeding disorder, platelet-type, 11 11.1
46 bleeding disorder, platelet-type, 15 11.1
47 bleeding disorder, platelet-type, 18 11.1
48 bleeding disorder, platelet-type, 19 11.1
49 bleeding disorder, platelet-type, 20 11.1
50 factor xiii deficiency 11.1

Graphical network of the top 20 diseases related to Blood Coagulation Disease:



Diseases related to Blood Coagulation Disease

Symptoms & Phenotypes for Blood Coagulation Disease

GenomeRNAi Phenotypes related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADAMTS13 ATAT1 CD40LG F2 F3 F7

MGI Mouse Phenotypes related to Blood Coagulation Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 ADAMTS13 ATAT1 CD40LG F2 F3 F8
2 homeostasis/metabolism MP:0005376 10.19 ADAMTS13 CD40LG F2 F3 F7 F8
3 cardiovascular system MP:0005385 10.1 CD40LG F2 F3 F7 F9 ITGA2B
4 embryo MP:0005380 9.97 F2 F3 F9 ITGA2B ITGB3 MPL
5 immune system MP:0005387 9.97 ADAMTS13 CD40LG F2 F3 F8 F9
6 mortality/aging MP:0010768 9.8 ADAMTS13 ATAT1 CD40LG F2 F3 F7
7 reproductive system MP:0005389 9.28 ATAT1 CD40LG F2 F8 ITGA2B ITGB3

Drugs & Therapeutics for Blood Coagulation Disease

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Dalteparin Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency. DB06779
2 Heparin Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values. DB01109
3 Nadroparin Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction. DB08813
4 Tinzaparin Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis. DB06822

Drugs for Blood Coagulation Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phylloquinone Approved, Investigational Phase 4 84-80-0
2
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
3
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
4
Tranexamic Acid Approved Phase 4 1197-18-8 5526
5 fluindione Approved, Investigational Phase 4 957-56-2
6
Phenindione Approved, Investigational Phase 4 83-12-5 4760
7
Protein C Approved Phase 4
8
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
9
Enoxaparin Approved Phase 4 9005-49-6 772
10
Dalteparin Approved Phase 4 9005-49-6
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Edoxaban Approved Phase 4 480449-70-5
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Thrombin Approved, Investigational Phase 4
15
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
18 Menaquinone Investigational Phase 4 1182-68-9
19 Hydroxyethyl Starch Derivatives Phase 4
20 Plasma Substitutes Phase 4
21 Blood Substitutes Phase 4
22 Micronutrients Phase 4
23 Trace Elements Phase 4
24 Coagulants Phase 4
25 Vitamins Phase 4
26 Antifibrinolytic Agents Phase 4
27 naphthoquinone Phase 4
28 Vitamin K Phase 4
29 Hemostatics Phase 4
30 Nutrients Phase 4
31 Fibrinolytic Agents Phase 4
32 Hirudins Phase 4
33 polysaccharide-K Phase 4
34 Calcium, Dietary Phase 4
35 Heparin, Low-Molecular-Weight Phase 4
36 Natriuretic Agents Phase 4
37 Deamino Arginine Vasopressin Phase 4
38 arginine Phase 4
39 Vasopressins Phase 4
40 Arginine Vasopressin Phase 4
41 calcium heparin Phase 4
42
protease inhibitors Phase 4
43 Antithrombin III Phase 4
44 HIV Protease Inhibitors Phase 4
45 Serine Proteinase Inhibitors Phase 4
46 Antithrombins Phase 4
47 Factor Xa Inhibitors Phase 4
48 Pharmaceutical Solutions Phase 4
49 Analgesics Phase 4
50 Cyclooxygenase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 364)
# Name Status NCT ID Phase Drugs
1 The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management Unknown status NCT00964353 Phase 4 Warfarin
2 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
3 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
4 Study Using Plasma for Patients Requiring Emergency Surgery: A Randomized Pilot Trial of Early Plasma for Patients Undergoing Emergency Surgery for Hemorrhagic Shock Unknown status NCT01221389 Phase 4 Human Plasma
5 A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery Completed NCT01487837 Phase 4 Human fibrinogen concentrate
6 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease. Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
7 rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa Completed NCT00571584 Phase 4 activated recombinant human factor VII
8 NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA® Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
9 An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors. Completed NCT02050841 Phase 4
10 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery. A Randomised Clinical Study Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
11 Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study Completed NCT00997841 Phase 4
12 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
13 Early Administration of Fibrinogen Concentrate in Polytraumatized Patients With Thromboelastometry Suggestive of Hypofibrinogenemia: a Randomized Feasibility Trial Completed NCT02864875 Phase 4 Fibrinogen concentrate
14 An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
15 Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients With Moderate or Severe Haemophilia A in India Completed NCT03449342 Phase 4 turoctocog alfa
16 Comparison of Three Management Strategies for Post Cardiac Surgery Coagulopathy. Completed NCT00188747 Phase 4
17 Coagulopathy During Surgery for the Repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - Feasibility Study of the Use of Fibrinogen Concentrate by Infusion in Place of Fresh Frozen Plasma. Completed NCT00994045 Phase 4
18 Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
19 A Prospective, Randomized Study of Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal at a Large Tertiary Care Medical Center Completed NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
20 The Assessment of the Minimal Effective and Tolerated Dose of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
21 The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass. Recruiting NCT02822599 Phase 4 RiaStAP;Saline
22 Bivalirudin vs Heparin in Elderly Patients With Acute Coronary Syndrome Undergoing Elective Percutaneous Coronary Intervention Recruiting NCT04046029 Phase 4 Bivalirudin;Heparin
23 Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical Patients Recruiting NCT02777424 Phase 4 Prothrombin Complex Concentrate
24 Profilatic Fibrinogen Concentrate Reduces Postoperative Bleeding in Pediatric Cardiac Surgery With Cardiopulmonary Bypass: Randomized Study Recruiting NCT03884725 Phase 4 Fibrinogen Concentrate
25 Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
26 Placebo-Controlled, Randomized, Double-Blind Trial of Prophylactic Desmopressin in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo
27 Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center. Enrolling by invitation NCT02557672 Phase 4 Prothrombin complex concentrate (Human)
28 Relationship of Edoxaban Plamsa Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis Not yet recruiting NCT03666650 Phase 4 Edoxaban 60 MG
29 Randomized Trial of Reinforcement Learning for the Dosing of Warfarin Not yet recruiting NCT03962400 Phase 4
30 Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery Not yet recruiting NCT03805607 Phase 4 Ketorolac Tromethamine 30 MG/ML;Placebos
31 Indicación de transfusión de Hemoderivados en el Postoperatorio de cirugía Cardiaca Tras la implantación de un Sistema de monitorización de la coagulación a la Cabecera Del Paciente: Tromboelastometría Versus Protocolo Habitual de transfusión Terminated NCT01919840 Phase 4
32 A Pilot Study to Compare the Use of Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Withdrawn NCT02774317 Phase 4
33 PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care Withdrawn NCT00377143 Phase 4 Warfarin Dosing
34 A Double-bline Safety and Efficacy Study Comparing Pad-gauze With Tranexamic Acid (Hemostopan™) to a Regular Pad-gauze in Controlling Bleeding in Patients on Hemodialysis. Unknown status NCT01854476 Phase 2, Phase 3
35 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
36 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding Completed NCT00708435 Phase 3
37 Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A Completed NCT01489111 Phase 3 turoctocog alfa pegol
38 Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors Completed NCT01392547 Phase 3 vatreptacog alfa (activated);eptacog alfa (activated)
39 An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B Completed NCT01386528 Phase 3 nonacog beta pegol
40 A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A Completed NCT01480180 Phase 3 turoctocog alfa pegol
41 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Completed NCT01178294 Phase 2, Phase 3
42 A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency Completed NCT00713648 Phase 3 catridecacog
43 Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage Completed NCT00127283 Phase 3 eptacog alfa (activated)
44 Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A Completed NCT01493778 Phase 3 turoctocog alfa
45 Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A Completed NCT02938585 Phase 3 turoctocog alfa;turoctocog alfa
46 A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A Completed NCT01731600 Phase 3 turoctocog alfa pegol
47 An Open-label, Uncontrolled, Single-arm, Multicenter Phase IIIb Study to Assess the Efficacy and Safety of BE1116 in Japanese Subjects Receiving Vitamin K Antagonist Therapy With an Elevated INR and Either Acute Major Bleeding or a Requirement for Urgent Reversal of Vitamin K Antagonist Therapy for a Surgical or Invasive Medical Procedure Completed NCT02281201 Phase 3
48 A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency Completed NCT00978380 Phase 3 catridecacog
49 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure Completed NCT00803101 Phase 3
50 A Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombi-nant Factor VIIa (rFVIIa/ NovoSeven®) With Standard Haemostatic Replacement Therapy, and Standard Haemostatic Replacement Ther-apy Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease Completed NCT01562574 Phase 3 activated recombinant human factor VII;placebo

Search NIH Clinical Center for Blood Coagulation Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Dalteparin
Heparin
Nadroparin
Tinzaparin
Tranexamic Acid
TRANEXAMIC ACID PWDR

Cochrane evidence based reviews: blood coagulation disorders

Genetic Tests for Blood Coagulation Disease

Anatomical Context for Blood Coagulation Disease

MalaCards organs/tissues related to Blood Coagulation Disease:

41
Testes, Liver, Brain, Heart, Whole Blood, Prostate, Kidney

Publications for Blood Coagulation Disease

Articles related to Blood Coagulation Disease:

(show top 50) (show all 441)
# Title Authors PMID Year
1
Contribution of nascent cohesive fiber-fiber interactions to the non-linear elasticity of fibrin networks under tensile load. 38
31152942 2019
2
[Blood Coagulation Disorders During ECMO and LVAD Therapy]. 38
31212331 2019
3
Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement. 38
31144420 2019
4
[The condition of the hemostatic system in acute severe peritonitis during remaxol therapy]. 38
30855593 2019
5
Distinct plasma proteomic changes in male and female African American stroke patients. 38
31149323 2019
6
[A case of congenital bile acid synthesis disorder type 2 and literature review]. 38
30298497 2018
7
The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions. 38
30005228 2018
8
Hemorrhagic Events in Adult Celiac Disease Patients. Case Report and Review of the Literature. 38
29557421 2018
9
Microbial serine protease inhibitors and their therapeutic applications. 38
28970170 2018
10
Correlations between lipid metabolism indices in patients with hypertension and hypothyroidism. 38
29729156 2018
11
Thrombosis in Thyroid Cancer. 38
29696039 2018
12
A User-Friendly App for Blood Coagulation Disorders. 38
29380340 2018
13
Hemostasis in Overt and Subclinical Hyperthyroidism. 38
29201071 2017
14
Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders. 38
29026409 2017
15
Thromboelastographic profile of goat blood after the experimental injury of the femoral artery and use of QuikClot gauze and Celox gauze dressings. 38
28525329 2017
16
Measuring coagulation in burns: an evidence-based systematic review. 38
29799542 2017
17
Novel combined strategy of obstetric haemorrhage management during caesarean section using intrauterine balloon tamponade. 38
26625194 2017
18
Treatment of Coagulopathy Related to Hepatic Insufficiency. 38
27635482 2016
19
Possibly propylthiouracil-induced antineutrophilic cytoplasmic antibody-associated vasculitis manifested as blood coagulation disorders: A case report. 38
27741122 2016
20
Biomedical and Catalytic Applications of Gold and Silver-Gold Alloy Nanoparticles Biosynthesized Using Cell-Free Extract of Bacillus Safensis LAU 13: Antifungal, Dye Degradation, Anti-Coagulant and Thrombolytic Activities. 38
27164598 2016
21
Protease-activated receptors - biology and role in cancer. 38
27383574 2016
22
Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics. 38
26116831 2016
23
A portable blood plasma clot micro-elastometry device based on resonant acoustic spectroscopy. 38
26233406 2015
24
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain. 38
26051726 2015
25
[Anesthesia and perioperative management for cesarean section in patient with factor XI deficiency: a case report]. 38
24743832 2014
26
A conformational investigation of propeptide binding to the integral membrane protein γ-glutamyl carboxylase using nanodisc hydrogen exchange mass spectrometry. 38
24512177 2014
27
Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa. 38
24412029 2014
28
[Features of coagulative blood potential disorder in acute constitutional inflammatory response of septic tubo-ovarian formations]. 38
25971120 2014
29
[Overview--Recent therapeutic strategy for blood coagulation disorders]. 38
24492038 2014
30
TURP and PVP treatments are really similar? From subjective feeling to objective data. Pilot study (proof of concept) prospective randomized trial. 38
23427748 2012
31
Quantification of circulating D-dimer by peptide immunoaffinity enrichment and tandem mass spectrometry. 38
22788854 2012
32
[Bundle program of treatment for acute severe type high altitude disease]. 38
22748458 2012
33
[Neonatal renal vein thrombosis in a heterozygous carrier of both factor V Leiden and the MTHFR gene mutation]. 38
22361411 2012
34
[Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique?]. 38
22154448 2012
35
Chapter 9: Analyses using disease ontologies. 38
23300417 2012
36
Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge. 38
21633664 2011
37
Malignant tumours of colon and rectum from the blood clotting view. 38
22180990 2011
38
D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C - role in prothrombotic state of colorectal cancer. 38
21391740 2011
39
Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. 38
20947138 2010
40
Spontaneous intramural duodenal haematoma with transient biliary obstruction and acute cholecystitis. 38
21221492 2010
41
Ophidian accident-related multi-organ failure: a case report. 38
25302518 2010
42
[Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period]. 38
21400731 2010
43
In silico studies of blood coagulation proteins: from mosaic proteases to nonenzymatic cofactor inhibitors. 38
20083402 2010
44
Purification and functional characterisation of rhinocerase, a novel serine protease from the venom of Bitis gabonica rhinoceros. 38
20300193 2010
45
Blood coagulation disorders in septic patients. 38
20364416 2010
46
Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin haemodilution. 38
19239406 2009
47
Atypical causes of nontraumatic intracranial subarachnoid hemorrhage. 38
19117667 2009
48
Effect of umbelliferone (7-hydroxycoumarin, 7-HOC) on the enzymatic, edematogenic and necrotic activities of secretory phospholipase A2 (sPLA2) isolated from Crotalus durissus collilineatus venom. 38
19470355 2009
49
Multiple gene interaction and modulation of hemostatic balance. 38
19824800 2009
50
[Blood coagulation disorders in children]. 38
19132176 2008

Variations for Blood Coagulation Disease

Expression for Blood Coagulation Disease

Search GEO for disease gene expression data for Blood Coagulation Disease.

Pathways for Blood Coagulation Disease

Pathways related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 VWF THPO THBD SERPINC1 PF4 MPL
2
Show member pathways
12.75 THBD SERPINC1 F9 F8 F7 F3
3
Show member pathways
12.1 THBD PF4 ITGB3 F2
4
Show member pathways
12.09 VWF ITGB3 ITGA2B GP9 GP1BA
5 12 VWF THBD SERPINC1 F9 F8 F7
6 11.92 VWF ITGB3 ITGA2B GP9 GP1BA
7 11.87 THPO MPL ITGB3 ITGA2B GP1BA
8
Show member pathways
11.79 F9 F7 F2
9 11.75 THPO ITGB3 ITGA2B GP9 GP1BA
10
Show member pathways
11.75 VWF THPO MPL ITGB3 ITGA2B GP9
11 11.68 VWF ITGB3 F3
12
Show member pathways
11.57 VWF THBD SERPINC1 PF4 GP9 GP1BA
13 11.43 VWF ITGB3 ITGA2B GP9 F2
14 11.39 ITGB3 ITGA2B GP9
15 10.88 F9 F7 F2
16 10.87 THPO PF4 ITGB3 ITGA2B CD40LG
17 10.8 VWF GP9 GP1BA
18 10.63 VWF GP9 GP1BA

GO Terms for Blood Coagulation Disease

Cellular components related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.73 VWF SERPINC1 PF4 F3
2 Golgi lumen GO:0005796 9.63 F9 F7 F2
3 endoplasmic reticulum lumen GO:0005788 9.63 SERPINC1 F9 F8 F7 F2 ADAMTS13
4 platelet alpha granule lumen GO:0031093 9.58 VWF PF4 F8
5 cell surface GO:0009986 9.56 THBD MPL ITGB3 ITGA2B GP1BA F3
6 platelet alpha granule membrane GO:0031092 9.48 ITGB3 ITGA2B
7 extracellular space GO:0005615 9.4 THPO THBD SERPINC1 PF4 GP1BA F9
8 serine-type peptidase complex GO:1905286 9.32 F7 F3
9 plasma membrane GO:0005886 10.18 THBD SERPINC1 MPL ITGB3 ITGA2B GP9
10 extracellular region GO:0005576 10 VWF THPO SERPINC1 PF4 F9 F8

Biological processes related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.81 F9 F8 F7 F2
2 platelet activation GO:0030168 9.81 VWF PF4 ITGB3 GP9 GP1BA F8
3 integrin-mediated signaling pathway GO:0007229 9.76 ITGB3 ITGA2B ADAMTS13
4 cell-matrix adhesion GO:0007160 9.75 ITGB3 ITGA2B ADAMTS13
5 blood coagulation, intrinsic pathway GO:0007597 9.73 VWF GP9 GP1BA F9 F8 F2
6 platelet degranulation GO:0002576 9.72 VWF PF4 ITGB3 ITGA2B F8
7 regulation of megakaryocyte differentiation GO:0045652 9.7 PF4 ITGA2B GP1BA
8 hemostasis GO:0007599 9.7 VWF THBD SERPINC1 GP9 GP1BA F9
9 protein processing GO:0016485 9.67 F7 F3 ADAMTS13
10 platelet aggregation GO:0070527 9.67 MPL ITGB3 ITGA2B GP1BA
11 cell-substrate adhesion GO:0031589 9.59 VWF ITGB3
12 regulation of blood coagulation GO:0030193 9.58 SERPINC1 GP1BA F2
13 positive regulation of blood coagulation GO:0030194 9.57 F7 F2
14 positive regulation of positive chemotaxis GO:0050927 9.56 F7 F3
15 negative regulation of fibrinolysis GO:0051918 9.55 THBD F2
16 negative regulation of platelet activation GO:0010544 9.54 THBD F2
17 thrombopoietin-mediated signaling pathway GO:0038163 9.48 THPO MPL
18 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.46 F7 F3
19 blood coagulation, extrinsic pathway GO:0007598 9.43 F7 F3
20 blood coagulation GO:0007596 9.4 VWF THBD SERPINC1 ITGB3 GP9 GP1BA
21 cell adhesion GO:0007155 10 VWF ITGB3 ITGA2B GP9 GP1BA

Molecular functions related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.56 F9 F7 F3 F2
2 fibrinogen binding GO:0070051 8.96 ITGB3 ITGA2B
3 protease binding GO:0002020 8.92 VWF SERPINC1 ITGB3 F3
4 protein binding GO:0005515 10.09 VWF U2AF1 THBD SERPINC1 PF4 MPL

Sources for Blood Coagulation Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....